Coya Therapeutics outlines biomarker stratification method for Phase 2/3 ALS trial
COYA•COYA•COYA•COYA•Coya Therapeutics will present its ALSTARS trial biomarker stratification method at the Annual NEALS Meeting on October 28, 2026. The ongoing Phase 2/3 trial evaluates COYA 302 against placebo, grouping participants by baseline neurofilament light chain levels to balance disease progression risk across treatment arms.
Coya Therapeutics will present its ALSTARS trial biomarker stratification methodology at the Annual NEALS Meeting on October 28, 2026, in Clearwater, Florida. The ongoing Phase 2/3 trial evaluates COYA 302’s efficacy and safety in amyotrophic lateral sclerosis against placebo, with participants grouped by baseline neurofilament light chain levels to balance disease progression risk across treatment arms. Coya believes the approach may reduce patient variability and improve assessment of treatment effects.
